Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Heart rate increases in liraglutide treated chronic heart failure patients: association with clinical parameters and adverse events: Liraglutide increases heart rate only in chronic heart failure patients with sinus rhythm and independently of beta-blocker dose

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Association between inflammatory markers and survival in comatose, resuscitated out-of-hospital cardiac arrest patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Three decades of heart transplantation: experience and long-term outcome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Patient-prioritized primary endpoints in clinical trials

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  4. Assessment of patients with a suspected cardioembolic ischemic stroke. A national consensus statement

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  5. Long-term prognosis following hospitalization for acute myocarditis - a matched nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Background. Liraglutide, a glucagon-like peptide-1 agonist, is used for treatment of type 2 diabetes and has beneficial cardiovascular properties. However, treatment increases heart rate (HR) and possibly the risk of cardiovascular events in chronic heart failure (CHF) patients. We investigated potential associations between HR changes and clinical, laboratory and echocardiographic parameters and clinical events in liraglutide treated CHF patients. Methods. This was a sub-study of the LIVE study. CHF patients (N = 241) with a left ventricular ejection fraction ≤45% were randomised to 1.8 mg liraglutide daily or placebo for 24 weeks. Electrocardiograms (N = 117) and readouts from cardiac implanted electronic devices (N = 20) were analysed for HR and arrhythmias. Results. In patients with sinus rhythm (SR), liraglutide increased HR by 8 ± 9 bpm (pulse measurements), 9 ± 9 bpm (ECG measurements) and 9 ± 6 bpm (device readouts) versus placebo (all p'.005). Increases in HR correlated with liraglutide dose (p=.01). HR remained unchanged in patients without SR. Serious cardiac adverse events were not associated with HR changes. Conclusions. During 6 months of treatment, HR increased substantially in CHF patients with SR treated with liraglutide but was not associated with adverse events. The long-term clinical significance of increased HR in liraglutide treated CHF patients needs to be determined.

TidsskriftScandinavian cardiovascular journal : SCJ
Udgave nummer5
Sider (fra-til)294-299
Antal sider6
StatusUdgivet - okt. 2020

ID: 59671775